Level Biotechnology (TWO:3118) — Stock Price
Level Biotechnology (TWO:3118) is currently trading at NT$32.00 TWD, down 1.84% today. Over the past 52 weeks, shares have ranged between NT$30.95 and NT$34.10. This page tracks Level Biotechnology's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Level Biotechnology market capitalisation.
Level Biotechnology (3118) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Level Biotechnology's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Level Biotechnology Income Statement — Revenue, Profit & Earnings by Year
Level Biotechnology's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | NT$731.35 Million | NT$660.61 Million | NT$593.01 Million | NT$677.28 Million | NT$672.49 Million |
| Cost of Revenue | NT$494.22 Million | NT$441.07 Million | NT$390.42 Million | NT$444.77 Million | NT$460.78 Million |
| Gross Profit | NT$237.13 Million | NT$219.54 Million | NT$202.59 Million | NT$232.50 Million | NT$211.71 Million |
| Research & Development | NT$12.95 Million | NT$13.77 Million | NT$14.03 Million | NT$15.02 Million | NT$13.70 Million |
| SG&A | NT$148.92 Million | NT$53.41 Million | NT$49.93 Million | NT$49.83 Million | NT$49.17 Million |
| Total Operating Expenses | NT$656.09 Million | NT$151.75 Million | NT$137.69 Million | NT$153.54 Million | NT$145.55 Million |
| Operating Income | NT$75.26 Million | NT$79.22 Million | NT$73.50 Million | NT$85.40 Million | NT$73.14 Million |
| EBITDA | — | NT$98.95 Million | NT$93.00 Million | NT$105.19 Million | NT$93.96 Million |
| EBIT | — | NT$79.22 Million | NT$73.50 Million | NT$85.40 Million | NT$73.14 Million |
| Interest Expense | NT$280.00K | NT$332.00K | NT$348.00K | NT$378.00K | NT$434.00K |
| Income Before Tax | NT$81.12 Million | NT$78.65 Million | NT$73.16 Million | NT$84.89 Million | NT$72.54 Million |
| Income Tax Expense | — | NT$15.74 Million | NT$14.69 Million | NT$16.71 Million | NT$14.50 Million |
| Net Income | NT$64.81 Million | NT$62.91 Million | NT$58.47 Million | NT$68.18 Million | NT$58.04 Million |
Level Biotechnology Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Level Biotechnology's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | NT$827.11 Million | NT$822.67 Million | NT$812.53 Million | NT$787.62 Million | NT$772.99 Million |
| Total Current Assets | NT$483.95 Million | NT$680.50 Million | NT$665.82 Million | NT$634.24 Million | NT$608.50 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | NT$112.09 Million | NT$124.21 Million | NT$128.61 Million | NT$105.10 Million | NT$164.34 Million |
| Inventory | NT$98.09 Million | NT$88.85 Million | NT$73.70 Million | NT$56.17 Million | NT$63.56 Million |
| Property, Plant & Equipment | — | — | NT$113.01 Million | NT$122.41 Million | NT$131.75 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$267.19 Million | NT$273.20 Million | NT$270.13 Million | NT$242.78 Million | NT$243.56 Million |
| Total Current Liabilities | NT$252.49 Million | NT$252.76 Million | NT$254.59 Million | NT$225.17 Million | NT$224.55 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | NT$-453.90 Million | NT$-450.76 Million | NT$-459.59 Million | NT$-364.44 Million |
| Total Stockholder Equity | NT$559.91 Million | NT$549.47 Million | NT$542.40 Million | NT$544.84 Million | NT$529.43 Million |
| Retained Earnings | NT$66.48 Million | NT$62.26 Million | NT$61.12 Million | NT$70.28 Million | NT$60.71 Million |
Level Biotechnology Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Level Biotechnology generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$64.10 Million | NT$70.21 Million | NT$65.07 Million | NT$155.95 Million | NT$83.23 Million |
| Capital Expenditures | NT$223.68 Million | NT$7.67 Million | NT$6.74 Million | NT$9.15 Million | NT$2.54 Million |
| Free Cash Flow | NT$-159.58 Million | NT$62.54 Million | NT$58.33 Million | NT$146.79 Million | NT$80.69 Million |
| Investing Cash Flow | — | — | NT$-10.19 Million | NT$-8.79 Million | NT$-2.63 Million |
| Financing Cash Flow | — | NT$-55.40 Million | NT$-64.34 Million | NT$-54.52 Million | NT$-44.69 Million |
| Dividends Paid | NT$-55.17 Million | NT$55.17 Million | NT$61.66 Million | NT$51.92 Million | NT$42.19 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | NT$21.21 Million | NT$19.72 Million | NT$19.50 Million | NT$19.79 Million | NT$20.83 Million |
| Change in Cash | NT$-214.62 Million | NT$3.91 Million | NT$-9.46 Million | NT$92.64 Million | NT$35.90 Million |
Level Biotechnology Earnings History — EPS Actual vs. Analyst Estimates
Track Level Biotechnology's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 29, 2025 | — | — | — |
| Mar 31, 2023 | 0.50 | — | — |
| Dec 31, 2022 | 0.53 | — | — |
| Sep 30, 2022 | 0.41 | — | — |
| Jun 30, 2022 | 0.52 | — | — |
| Mar 31, 2022 | 0.34 | — | — |
| Dec 31, 2021 | 0.48 | — | — |
| Sep 30, 2021 | 0.57 | — | — |